Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | ABL1 | P00519 | 1/20 | 0.69 |
| ▸ | ABL2 | P42684 | 1/20 | 0.69 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.69 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13234498 | 0.89 | LMNA (1.00) | MAPK14LMNAABL1ABL2MAPK8 | |
| SCHEMBL667738 | 0.87 | MAPK14 (1.00) | MAPK14LMNAABL1ABL2MAPK8 | |
| SCHEMBL2616949 | 0.85 | MAPK14 (1.00) | MAPK14ABL1ABL2MAPK8MAPK11 | |
| SCHEMBL669021 | 0.84 | MAPK14 (0.81) | MAPK14LMNAABL1ABL2MAPK8 | |
| SCHEMBL5743898 | 0.84 | MAPK14 (1.00) | MAPK14ABL1ABL2MAPK8MAPK11 | |
| SCHEMBL8737816 | 0.84 | MAPK14 (0.81) | MAPK14LMNAABL1ABL2MAPK8 | |
| SCHEMBL667859 | 0.83 | MAPK14 (1.00) | MAPK14LMNAABL1ABL2MAPK8 | |
| SCHEMBL5733797 | 0.83 | MAPK14 (1.00) | MAPK14ABL1ABL2MAPK8MAPK11 | |
| SCHEMBL9903976 | 0.83 | MAPK14 (0.82) | MAPK14LMNAABL1ABL2MAPK8 | |
| SCHEMBL668113 | 0.83 | MAPK14 (1.00) | MAPK14LMNAABL1ABL2MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | claimed |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2012-02-23 | — | — | US | claimed |
| EP-1041982-B1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC (US) | 2011-10-19 | — | — | EP | claimed |
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2012-02-23 | — | — | US | disclosed |
| EP-1041982-B1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-1041982-A4 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1041982-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032111-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | MAPK1, MAP3K1, MAP3K7 | MAPK14 31/4885LMNA 3582/4885ABL1 139/4885 |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | MAPK1, MAP3K1, MAP3K7 | MAPK14 31/4885LMNA 3582/4885ABL1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.